Xencor/$XNCR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Xencor

Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.

Ticker

$XNCR
Primary listing

Industry

Biotechnology

Employees

250

ISIN

US98401F1057

Xencor Metrics

BasicAdvanced
$598M
-
-$3.05
0.87
-

What the Analysts think about Xencor

Analyst ratings (Buy, Hold, Sell) for Xencor stock.

Bulls say / Bears say

Xencor's strategic partnerships, including a restructured agreement with Genentech that could yield up to $600 million in milestones, enhance its financial stability and extend its cash runway into 2027. (markets.businessinsider.com)
The company's focus on T-cell engagers is validated by promising data from Amgen's AMG509, developed using Xencor's technology, indicating potential for significant advancements in cancer treatment. (markets.businessinsider.com)
Analysts maintain a 'Strong Buy' consensus rating for Xencor, with an average price target of $38.75, suggesting a potential upside of over 100% from current levels. (markets.businessinsider.com)
StockNews.com downgraded Xencor's rating from 'hold' to 'sell' in March 2025, indicating potential concerns about the company's near-term performance. (marketbeat.com)
Despite better-than-expected earnings, Xencor reported a net loss of $53.48 million in Q4 2024, reflecting ongoing financial challenges. (marketbeat.com)
The company's stock price has experienced significant volatility, trading as low as $12.69 and as high as $27.24 over the past year, which may concern risk-averse investors. (marketbeat.com)
Data summarised monthly by Lightyear AI. Last updated on 11 Jun 2025.

Xencor Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Xencor Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $XNCR

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs